University of Leeds Collaborates on Prolaris Clinical Utility Study

Long-term study demonstrates improved clinical outcomes for patients.

“The use of a combined clinical and molecular score (CCR) has been shown to provide significantly improved prognostic information over clinicopathologic factors alone. […] The durability of AS was similar to previously published rates, with approximately two-thirds of patients remaining on active surveillance (AS) after 4 years; however, the increased AS selection rate at the time of diagnosis reported here increased the overall number of men who remained on AS.”

Kaul S, et al. Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell-cycle risk score. Per Med. 2019 Sep 4. [ePub ahead of print.]

Learn More View Article

Significant impact on personalized treatment decisions.

“The cell cycle progression test has a significant impact in assisting physicians and patients reach personalized treatment decisions.”

Shore N, Kella N, Moran B, et al. Impact of the cell cycle progression test on physician and patient treatment selection for localized prostate cancer. J Urol 2016 March; 195:612-18.

Learn More View Article

Physicians ordering Prolaris modified treatment decisions.

“Test results led to changes in treatment with reductions and increases in interventional treatment that were directionally aligned with prostate cancer risk specified by the test.”

Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin 2014 Jun; 30(6):1025-31.

Request Full Article View Abstract